Segall Bryant & Hamill LLC Sells 16,328 Shares of Phibro Animal Health Corporation $PAHC

Segall Bryant & Hamill LLC decreased its position in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 13.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 104,301 shares of the company’s stock after selling 16,328 shares during the period. Segall Bryant & Hamill LLC’s holdings in Phibro Animal Health were worth $5,769,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Bank of America Corp DE lifted its stake in Phibro Animal Health by 22.6% during the first quarter. Bank of America Corp DE now owns 78,957 shares of the company’s stock worth $4,367,000 after purchasing an additional 14,536 shares during the last quarter. Systematic Alpha Investments LLC bought a new stake in shares of Phibro Animal Health during the 1st quarter worth $293,000. Amundi acquired a new stake in Phibro Animal Health in the first quarter valued at about $539,000. EverSource Wealth Advisors LLC grew its position in Phibro Animal Health by 19.0% in the first quarter. EverSource Wealth Advisors LLC now owns 5,907 shares of the company’s stock valued at $327,000 after acquiring an additional 943 shares during the last quarter. Finally, California State Teachers Retirement System raised its stake in Phibro Animal Health by 19.9% during the first quarter. California State Teachers Retirement System now owns 22,515 shares of the company’s stock worth $1,245,000 after acquiring an additional 3,735 shares in the last quarter. 99.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Phibro Animal Health news, CEO Jack Bendheim sold 4,528 shares of Phibro Animal Health stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $48.49, for a total value of $219,562.72. Following the completion of the sale, the chief executive officer directly owned 56,152 shares of the company’s stock, valued at approximately $2,722,810.48. The trade was a 7.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 50.13% of the company’s stock.

Phibro Animal Health Price Performance

PAHC stock opened at $37.15 on Tuesday. The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of 15.94, a PEG ratio of 0.51 and a beta of 0.46. The company’s fifty day simple moving average is $32.78 and its 200 day simple moving average is $43.15. Phibro Animal Health Corporation has a 12-month low of $26.08 and a 12-month high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.04. The firm had revenue of $383.54 million during the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, analysts expect that Phibro Animal Health Corporation will post 3.08 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Wednesday, September 2nd will be given a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, September 2nd. This represents a $0.48 annualized dividend and a dividend yield of 1.3%. Phibro Animal Health’s dividend payout ratio (DPR) is 20.60%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on PAHC shares. Wall Street Zen lowered shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings downgraded shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. Citigroup cut their price objective on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a report on Thursday, May 14th. Finally, Zacks Research cut Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Phibro Animal Health presently has an average rating of “Hold” and a consensus price target of $42.50.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.